| | |
PER ADS
|
| |
TOTAL
|
| ||||||
公开发行价 | | | | $ | 10.00 | | | | | $ | 30,000,000 | | |
承保折扣和佣金(1) | | | | $ | 0.70 | | | | | $ | 2,100,000 | | |
未扣除费用的收益 | | | | $ | 9.30 | | | | | $ | 27,900,000 | | |
| | |
Page
|
| |||
PROSPECTUS SUMMARY
|
| | | | 1 | | |
THE OFFERING
|
| | | | 11 | | |
SUMMARY FINANCIAL DATA
|
| | | | 13 | | |
RISK FACTORS
|
| | | | 15 | | |
有关前瞻性陈述的警示说明
|
| | | | 95 | | |
市场、行业等数据
|
| | | | 97 | | |
USE OF PROCEEDS
|
| | | | 98 | | |
DIVIDEND POLICY
|
| | | | 99 | | |
CAPITALIZATION
|
| | | | 100 | | |
DILUTION
|
| | | | 101 | | |
选定的财务数据
|
| | | | 103 | | |
管理层对财务状况和经营成果的讨论和分析
|
| | | | 105 | | |
BUSINESS
|
| | | | 119 | | |
MANAGEMENT
|
| | | | 182 | | |
关联方交易
|
| | | | 196 | | |
主要股东
|
| | | | 197 | | |
股本说明
|
| | | | 199 | | |
美国存托股份说明
|
| | | | 212 | | |
未来有资格出售的普通股和美国存托凭证
|
| | | | 220 | | |
TAXATION
|
| | | | 223 | | |
UNDERWRITING
|
| | | | 231 | | |
EXPENSES OF THE OFFERING
|
| | | | 237 | | |
LEGAL MATTERS
|
| | | | 238 | | |
EXPERTS
|
| | | | 239 | | |
诉讼程序的送达和民事责任的执行
|
| | | | 240 | | |
您可以在哪里找到更多信息
|
| | | | 241 | | |
财务报表索引
|
| | | | F-1 | | |
| | |
For the Years Ended
December 31, |
| |
For the Nine Months Ended
September 30, |
| ||||||||||||||||||
| | |
(单位为千美元,每股数据除外)
|
| |||||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2019
|
| |
2020
|
| ||||||||||||
| | | | | | | | | | | | | | |
(unaudited)
|
| |||||||||
研发费用
|
| | | $ | 3,729 | | | | | $ | 8,216 | | | | | | 5,270 | | | | | | 8,048 | | |
一般和行政费用
|
| | | | 1,898 | | | | | | 2,647 | | | | | | 1,870 | | | | | | 3,875 | | |
Operating loss
|
| | | | (5,627) | | | | | | (10,863) | | | | | | (7,140) | | | | | | (11,923) | | |
Finance income
|
| | | | 76 | | | | | | 65 | | | | | | 84 | | | | | | 123 | | |
Finance expense
|
| | | | (719) | | | | | | (1,222) | | | | | | (1,186) | | | | | | (9) | | |
Net loss before tax
|
| | | | (6,270) | | | | | | (12,020) | | | | | | (8,242) | | | | | | (11,809) | | |
Income taxes
|
| | | | 735 | | | | | | 825 | | | | | | 566 | | | | | | 1,055 | | |
Net loss for the period
|
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (7,676) | | | | | $ | (10,754) | | |
Evaxion股东应占净亏损
Biotech A/S |
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (7,676) | | | | | $ | (10,754) | | |
Loss per share – basic and diluted(1)
|
| | | $ | (0.43) | | | | | $ | (0.81) | | | | | $ | (0.57) | | | | | $ | (0.71) | | |
| | |
As of September 30, 2020
|
| |||||||||||||||
| | |
Actual
|
| |
Pro
Forma(1) |
| |
Pro Forma
As Adjusted(2) |
| |||||||||
(in thousands) | | | | | | | | | | | | | | | |||||
合并财务状况表: | | | | | | | | | | | | | | | |||||
Cash and cash equivalents
|
| | | $ | 7,876 | | | | | $ | 10,268 | | | | | $ | 36,605 | | |
Total assets
|
| | | | 11,275 | | | | | | 13,667 | | | | | | 39,373 | | |
Total liabilities
|
| | | | 3,372 | | | | | | 3,372 | | | | | | 3,372 | | |
Share capital
|
| | | | 2,603 | | | | | | 2,645 | | | | | | 3,125 | | |
Other reserves
|
| | | | 29,067 | | | | | | 31,417 | | | | | | 56,643 | | |
Accumulated deficit
|
| | | | (23,767) | | | | | | (23,767) | | | | | | (23,767) | | |
Total equity
|
| | | $ | 7,903 | | | | | $ | 10,295 | | | | | $ | 36,001 | | |
(除每股和每股数据外,以千为单位)
|
| |
Actual
|
| |
Pro Forma
|
| |
Pro Forma
As Adjusted |
| |||||||||
现金和现金等价物
|
| | | $ | 7,876 | | | | | $ | 10,268 | | | | | $ | 36,605 | | |
Total liabilities
|
| | | | 3,372 | | | | | | 3,372 | | | | | | 3,372 | | |
Equity | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 2,603 | | | | | | 2,645 | | | | | | 3,125 | | |
其他储量
|
| | | | 29,067 | | | | | | 31,417 | | | | | | 56,643 | | |
Accumulated deficit
|
| | | | (23,767) | | | | | | (23,767) | | | | | | (23,767) | | |
Total equity
|
| | | | 7,903 | | | | | | 10,295 | | | | | | 36,001 | | |
总市值
|
| | | $ | 11,275 | | | | | $ | 13,667 | | | | | $ | 39,373 | | |
|
每个美国存托股份的首次公开募股价格
|
| | | | | | | | | $ | 10.00 | | |
|
截至2020年9月30日的历史美国存托股份有形账面净值
|
| | | | 0.45 | | | | | | | | |
|
美国存托股份在本次发行完成前发行和出售269,136股普通股,预计有形账面净值增加
|
| | | | 0.14 | | | | | | | | |
|
预计截至2020年9月30日的美国存托股份有形账面净值
|
| | | | 0.59 | | | | | | | | |
|
可归因于新投资者的美国存托股份预计有形账面净值增加
参与此次活动 |
| | | | 1.28 | | | | | | | | |
|
预计上市后每个美国存托股份的调整后有形账面净值
|
| | | | | | | | | | 1.87 | | |
|
按美国存托股份向参与此次发行的新投资者摊薄
|
| | | | | | | | | $ | 8.13 | | |
| | |
Ordinary Shares
Purchased |
| |
Total Consideration
|
| |
Average
Price Per Share |
| |
Average
Price Per ADS |
| ||||||||||||||||||||||||
| | |
Number
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| ||||||||||||||||||||||||
现有股东
|
| | | | 16,198,668 | | | | | | 84.4% | | | | | $ | 34,062,000 | | | | | | 53.2% | | | | | $ | 2.10 | | | | | $ | 2.10 | | |
New investors
|
| | | | 3,000,000 | | | | | | 15.6% | | | | | | 30,000,000 | | | | | | 46.8% | | | | | | 10.00 | | | | | | 10.00 | | |
Total
|
| | | | 19,198,668 | | | | | | 100% | | | | | $ | 64,062,000 | | | | | | 100% | | | | | $ | 3.34 | | | | | $ | 3.34 | | |
| | |
For the Years Ended
December 31, |
| |
For the Nine Months Ended
September 30, |
| ||||||||||||||||||
| | |
(单位为千美元,每股数据除外)
|
| |||||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2019
|
| |
2020
|
| ||||||||||||
| | | | | | | | | | | | | | |
(unaudited)
|
| |||||||||
研发费用
|
| | | $ | 3,729 | | | | | $ | 8,216 | | | | | | 5,270 | | | | | | 8,048 | | |
一般和行政费用
|
| | | | 1,898 | | | | | | 2,647 | | | | | | 1,870 | | | | | | 3,875 | | |
Operating loss
|
| | | | (5,627) | | | | | | (10,863) | | | | | | (7,140) | | | | | | (11,923) | | |
Finance income
|
| | | | 76 | | | | | | 65 | | | | | | 84 | | | | | | 123 | | |
Finance expense
|
| | | | (719) | | | | | | (1,222) | | | | | | (1,186) | | | | | | (9) | | |
Net loss before tax
|
| | | | (6,270) | | | | | | (12,020) | | | | | | (8,242) | | | | | | (11,809) | | |
Income taxes
|
| | | | 735 | | | | | | 825 | | | | | | 566 | | | | | | 1,055 | | |
Net loss for the period
|
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (7,676) | | | | | $ | (10,754) | | |
Evaxion Biotech股东应占净亏损
A/S |
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (7,676) | | | | | $ | (10,754) | | |
Loss per share – basic and diluted
|
| | | $ | (0.43) | | | | | $ | (0.81) | | | | | $ | (0.57) | | | | | $ | (0.71) | | |
| | |
As of
|
| |||||||||||||||
| | |
December 31,
|
| |
September 30,
|
| ||||||||||||
| | |
2018
|
| |
2019
|
| |
2020
|
| |||||||||
(in thousands)
|
| | | | | | | | | | | | | |
(unaudited)
|
| |||
合并财务状况表: | | | | | | | | | | | | | | | | | | | |
现金和现金等价物
|
| | | $ | 7,433 | | | | | $ | 9,559 | | | | | $ | 7,876 | | |
Total assets
|
| | | | 8,513 | | | | | | 11,084 | | | | | | 11,275 | | |
Total liabilities
|
| | | | 9,444 | | | | | | 1,722 | | | | | | 3,372 | | |
Share capital
|
| | | | 2,113 | | | | | | 2,481 | | | | | | 2,603 | | |
Other reserves
|
| | | | 3,935 | | | | | | 22,693 | | | | | | 29,067 | | |
Accumulated deficit
|
| | | | (6,979) | | | | | | (15,812) | | | | | | (23,767) | | |
Total equity
|
| | | | (931) | | | | | | 9,362 | | | | | | 7,903 | | |
| | |
截至9月30日的9个月
|
| | | | | | | |||||||||
| | |
2019
|
| |
2020
|
| |
Change
|
| |||||||||
| | |
(USD in thousands)
|
| | ||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 5,270 | | | | | $ | 8,048 | | | | | $ | 2,778 | | |
一般和行政
|
| | | | 1,870 | | | | | | 3,875 | | | | | | 2,005 | | |
总运营费用
|
| | | | 7,140 | | | | | | 11,923 | | | | | | 4,783 | | |
Operating loss
|
| | | | (7,140) | | | | | | (11,923) | | | | | | (4,783) | | |
Finance income
|
| | | | 84 | | | | | | 123 | | | | | | 39 | | |
Finance expenses
|
| | | | (1,186) | | | | | | (9) | | | | | | 1,177 | | |
Net loss before tax
|
| | | | (8,242) | | | | | | (11,809) | | | | | | (3,567) | | |
Income taxes
|
| | | | 566 | | | | | | 1,055 | | | | | | 489 | | |
Net loss for the period
|
| | | $ | (7,676) | | | | | $ | (10,754) | | | | | $ | (3,078) | | |
| | |
September 30, 2020
|
| |||||||||||||||||||||||||||||||||
(USD in thousands)
|
| |
Carrying
amount |
| |
Contractual
cash flows |
| |
|
| |
1 – 5 years
|
| |
>5 years
|
| |
Total
|
| ||||||||||||||||||
Lease liabilities
|
| | | $ | 38 | | | | | $ | 38 | | | | | $ | 38 | | | | | $ | — | | | | | $ | — | | | | | $ | 38 | | |
Trade payables
|
| | | | 1,502 | | | | | | 1,502 | | | | | | 1,502 | | | | | | — | | | | | | — | | | | | | 1,502 | | |
Other payables
|
| | | | 1,832 | | | | | | 1,832 | | | | | | 1,832 | | | | | | — | | | | | | — | | | | | | 1,832 | | |
Total
|
| | | $ | 3,372 | | | | | $ | 3,372 | | | | | $ | 3,372 | | | | | $ | — | | | | | $ | — | | | | | $ | 3,372 | | |
| | |
截至9月30日的9个月
|
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(USD in thousands)
|
| |||||||||
Cash Flow Data: | | | | | | | | | | | | | |
经营活动中使用的净现金
|
| | | $ | (4,812) | | | | | $ | (8,045) | | |
投资活动中使用的净现金
|
| | | | (14) | | | | | | (112) | | |
融资活动提供的现金净额
|
| | | | 9,264 | | | | | | 6,444 | | |
现金和现金等价物净增长
|
| | | $ | 4,438 | | | | | $ | (1,713) | | |
| | |
Years Ended December 31,
|
| | | | | | | |||||||||
| | |
2018
|
| |
2019
|
| |
Change
|
| |||||||||
| | |
(USD in thousands,
except per share amounts) |
| |||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 3,729 | | | | | $ | 8,216 | | | | | $ | 4,487 | | |
一般和行政
|
| | | | 1,898 | | | | | | 2,647 | | | | | | 749 | | |
总运营费用
|
| | | | 5,627 | | | | | | 10,863 | | | | | | 5,236 | | |
Operating loss
|
| | | | (5,627) | | | | | | (10,863) | | | | | | (5,236) | | |
Finance income
|
| | | | 76 | | | | | | 65 | | | | | | (11) | | |
Finance expenses
|
| | | | (719) | | | | | | (1,222) | | | | | | (503) | | |
Net loss before tax
|
| | | | (6,270) | | | | | | (12,020) | | | | | | (5,750) | | |
Income taxes
|
| | | | 735 | | | | | | 825 | | | | | | 90 | | |
Net loss for the year
|
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (5,660) | | |
| | |
Years Ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(USD in thousands)
|
| |||||||||
Cash Flow Data: | | | | | | | | | | | | | |
经营活动中使用的净现金
|
| | | $ | (1,978) | | | | | $ | (7,026) | | |
投资活动中使用的净现金
|
| | | | (7) | | | | | | (61) | | |
融资活动提供的现金净额
|
| | | | 9,027 | | | | | | 9,508 | | |
现金和现金等价物净增长
|
| | | $ | 7,042 | | | | | $ | 2,421 | | |
| | |
Payments Due by Period
|
| |||||||||||||||||||||||||||
(USD in thousands)
|
| |
Within 1 Year
|
| |
1 – 2 Years
|
| |
2 – 5 Years
|
| |
Over 5 Years
|
| |
Total
|
| |||||||||||||||
Leases
|
| | | $ | 55 | | | | | $ | – | | | | | $ | – | | | | | $ | – | | | | | $ | 55 | | |
Purchase obligations(1)
|
| | | | 587 | | | | | | 103 | | | | | | 20 | | | | | | – | | | | | | 710 | | |
Total(2)(3)(4)
|
| | | $ | 642 | | | | | $ | 103 | | | | | $ | 20 | | | | | $ | – | | | | | $ | 765 | | |
Outstanding program
|
| |
Per warrant
weighted average grant date fair value (DKK) |
| |
Per warrant
weighted average grant date fair value (USD) |
| ||||||
Grant (December 2016)
|
| | | | 20.91 | | | | | | 3.13 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 3.60 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 4.30 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 4.30 | | |
Granted (during 2018)
|
| | | | 37.05 | | | | | | 5.55 | | |
Granted (January 2019)
|
| | | | 37.05 | | | | | | 5.55 | | |
Granted (February 2019)
|
| | | | 42.57 | | | | | | 6.38 | | |
Granted (September 2019)
|
| | | | 56.35 | | | | | | 8.44 | | |
Granted (October 2019)
|
| | | | 56.97 | | | | | | 8.53 | | |
Bacterial species
|
| |
In vivo
PoC |
| |
体内模型(小鼠挑战模型)
|
| |
IP
filed |
|
金黄色葡萄球菌
|
| |
✓
|
| | 致死性腹膜炎和皮肤脓肿模型 | | |
✓
|
|
铜绿假单胞菌
|
| |
✓
|
| | 致死性腹膜炎和致死性急性肺炎模型 | | |
✓
|
|
非分型流感嗜血杆菌
|
| |
✓
|
| | 肺定植模型 | | |
✓
|
|
卡他莫拉氏菌
|
| |
✓
|
| | 致死性腹膜炎和肺定植模型 | | |
✓
|
|
淋病奈瑟菌
|
| |
✓
|
| | 阴道定植模型 | | |
✓
|
|
鲍曼不动杆菌
|
| |
✓
|
| | 致死性急性肺炎模型 | | |
✓
|
|
肺炎克雷伯菌
|
| |
✓
|
| | 致死性腹膜炎和致死性急性肺炎模型 | | |
✓
|
|
|
#
|
| |
Protein ID
|
| |
No. of
Experiments |
| |
No. of
Test Mice |
| |
No. of
Control Mice |
| |
%
Survival of Test Mice |
| |
%
Survival of Control Mice |
| |
Difference in
% Survival (Test vs. Control) |
| |||||||||||||||||||||
|
1
|
| | | | 伊甸园-1 | | | | | | 4 | | | | | | 59 | | | | | | 60 | | | | | | 76% | | | | | | 28% | | | | | | 48% | | |
|
2
|
| | | | 伊甸园-2 | | | | | | 2 | | | | | | 24 | | | | | | 24 | | | | | | 58% | | | | | | 13% | | | | | | 46% | | |
|
3
|
| | | | 伊甸园-3 | | | | | | 3 | | | | | | 43 | | | | | | 44 | | | | | | 77% | | | | | | 32% | | | | | | 45% | | |
|
4
|
| | | | 伊甸园-4 | | | | | | 2 | | | | | | 28 | | | | | | 28 | | | | | | 68% | | | | | | 25% | | | | | | 43% | | |
|
5
|
| | | | 伊甸园-5 | | | | | | 2 | | | | | | 28 | | | | | | 28 | | | | | | 68% | | | | | | 25% | | | | | | 43% | | |
|
6
|
| | | | 伊甸园-6 | | | | | | 2 | | | | | | 27 | | | | | | 28 | | | | | | 85% | | | | | | 43% | | | | | | 42% | | |
|
7
|
| | | | 伊甸园-7 | | | | | | 3 | | | | | | 36 | | | | | | 36 | | | | | | 61% | | | | | | 19% | | | | | | 42% | | |
|
8
|
| | | | 伊甸园-8 | | | | | | 5 | | | | | | 61 | | | | | | 64 | | | | | | 51% | | | | | | 9% | | | | | | 41% | | |
|
9
|
| | | | 伊甸园-9 | | | | | | 3 | | | | | | 43 | | | | | | 44 | | | | | | 63% | | | | | | 30% | | | | | | 33% | | |
|
10
|
| | | | 伊甸园-10 | | | | | | 3 | | | | | | 36 | | | | | | 36 | | | | | | 69% | | | | | | 36% | | | | | | 33% | | |
|
11
|
| | | | 伊甸园-11 | | | | | | 3 | | | | | | 32 | | | | | | 35 | | | | | | 53% | | | | | | 20% | | | | | | 33% | | |
|
12
|
| | | | 伊甸园-12 | | | | | | 3 | | | | | | 42 | | | | | | 42 | | | | | | 62% | | | | | | 31% | | | | | | 31% | | |
|
13
|
| | | | 伊甸园-13 | | | | | | 3 | | | | | | 36 | | | | | | 36 | | | | | | 47% | | | | | | 28% | | | | | | 19% | | |
|
|
| |
|
|
Function
|
| |
Number
|
| |||
临床研究与开发
|
| | | | 6 | | |
科学研究与开发
|
| | | | 21 | | |
Supporting Functions
|
| | | | 4 | | |
商业和商业发展
|
| | | | 4 | | |
TOTAL
|
| | |
|
35
|
| |
Region
|
| |
Number
|
| |||
Capital Region, Denmark
|
| | | | 34 | | |
New York, United States
|
| | | | 1 | | |
TOTAL
|
| | |
|
35
|
| |
Name
|
| |
Position
|
| |
Age
|
| |
Independent
|
| |
Year of first
appointment |
| |
Expiration
of current term |
|
Marianne Søgaard(1)
|
| | Member | | |
52
|
| |
No
|
| |
2020
|
| |
2021
|
|
Steven Projan(2)(3)
|
| | Member | | |
68
|
| |
Independent
|
| |
2018
|
| |
2021
|
|
Roberto Prego(1)(2)
|
| | Member | | |
50
|
| |
Independent
|
| |
2018
|
| |
2021
|
|
Jo Ann Suzich(3)
|
| | Member | | |
65
|
| |
Independent
|
| |
2019
|
| |
2021
|
|
Helen M. Boudreau(2)
|
| | Member | | |
54
|
| |
Independent
|
| |
2020
|
| |
2021
|
|
Name
|
| |
Age
|
| |
Position(s)
|
| |||
执行管理层: | | | | | | | | | | |
Lars Staal Wegner, M.D.
|
| | | | 46 | | | | 首席执行官 | |
Glenn S. Vraniak
|
| | | | 58 | | | | 首席财务官 | |
Erik Deichmann Heegaard,博士,DMSc
|
| | | | 53 | | | | 首席医疗官 | |
Niels Iversen Møller, M.D.
|
| | | | 42 | | | | 首席商务官 | |
Andreas Holm Mattsson
|
| | | | 45 | | | | 首席创新官 | |
| | |
Years Ended
December 31, |
| |||||||||
(in thousands of USD)
|
| |
2018
|
| |
2019
|
| ||||||
Lars Staal Wegner(CEO) | | | | | | | | | | | | | |
Salary
|
| | | | 220 | | | | | | 238 | | |
Bonus
|
| | | | 6 | | | | | | 0 | | |
其他员工福利
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | | 226 | | | | | | 238 | | |
Glenn S. Vraniak (CFO) | | | | | | | | | | | | | |
Salary
|
| | | | 0 | | | | | | 88 | | |
Bonus
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | | 0 | | | | | | 88 | | |
Niels Iverson Møller (CBO) | | | | | | | | | | | | | |
Salary
|
| | | | 173 | | | | | | 175 | | |
Bonus
|
| | | | 5 | | | | | | 0 | | |
其他员工福利
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | | 178 | | | | | | 175 | | |
安德烈亚斯·霍姆·马特森(CIO) | | | | | | | | | | | | | |
Salary
|
| | | | 179 | | | | | | 175 | | |
Bonus
|
| | | | 5 | | | | | | 0 | | |
其他员工福利
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | | 184 | | | | | | 175 | | |
| | |
Years Ended
December 31, |
| |||||||||
(in thousands of USD)
|
| |
2018
|
| |
2019
|
| ||||||
不包括执行管理层和董事会的员工成本 | | | | | | | | | | | | | |
Salaries
|
| | | | 1,112 | | | | | | 1,919 | | |
Cash bonus
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 387 | | | | | | 1,055 | | |
Pensions
|
| | | | 70 | | | | | | 96 | | |
其他社保缴费
|
| | | | 10 | | | | | | 12 | | |
Other staff costs
|
| | | | 133 | | | | | | 176 | | |
员工总成本,不包括执行管理层和董事会
|
| | | | 1,712 | | | | | | 3,258 | | |
高管薪酬 | | | | | | | | | | | | | |
Salaries
|
| | | | 621 | | | | | | 900 | | |
Cash bonus
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 1,157 | | | | | | 956 | | |
Pensions
|
| | | | 0 | | | | | | 0 | | |
其他社保缴费
|
| | | | 0 | | | | | | 0 | | |
Other staff costs
|
| | | | 0 | | | | | | 0 | | |
高管薪酬总额
|
| | | | 1,778 | | | | | | 1,856 | | |
董事会薪酬 | | | | | | | | | | | | | |
Board and committee fees
|
| | | | 0 | | | | | | 0 | | |
Travel allowance
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 525 | | | | | | 351 | | |
董事会薪酬总额
|
| | | | 525 | | | | | | 351 | | |
Total employee costs
|
| | | | 4,015 | | | | | | 5,465 | | |
在全面损失表中确认如下: | | | | | | | | | | | | | |
研发费用
|
| | | | 2,652 | | | | | | 3,607 | | |
一般和行政费用
|
| | | | 1,363 | | | | | | 1,858 | | |
Total employee costs
|
| | | | 4,015 | | | | | | 5,465 | | |
全职员工平均人数
|
| | | | 18 | | | | | | 25 | | |
Number of full-time employees – December 31, 2019
|
| | | | 20 | | | | | | 36 | | |
| | |
Years Ended
December 31, |
| |||||||||
(in thousands of DKK)
|
| |
2018
|
| |
2019
|
| ||||||
Kim Bjoernstrup(董事会主席)(1) | | | | | | | | | | | | | |
Board and committee fees
|
| | | | 0 | | | | | | 0 | | |
Travel allowance
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | | 0 | | | | | | 0 | | |
|
| | |
Years Ended
December 31, |
| |||||||||
(in thousands of DKK)
|
| |
2018
|
| |
2019
|
| ||||||
Helen M. Boudreau | | | | | | | | | | | | | |
Board and committee fees
|
| | | | 0 | | | | | | 0 | | |
Travel allowance
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 0 | | | | | | 0 | | |
Total
|
| | | | 0 | | | | | | 0 | | |
Roberto Prego | | | | | | | | | | | | | |
Board and committee fees
|
| | | | 0 | | | | | | 0 | | |
Travel allowance
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 0 | | | | | | 410 | | |
Total
|
| | | | 0 | | | | | | 410 | | |
Steven Projan | | | | | | | | | | | | | |
Board and committee fees
|
| | | | 0 | | | | | | 0 | | |
Travel allowance
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 868 | | | | | | 654 | | |
Total
|
| | | | 868 | | | | | | 654 | | |
Jo Ann Suzich | | | | | | | | | | | | | |
Board and committee fees
|
| | | | 0 | | | | | | 0 | | |
Travel allowance
|
| | | | 0 | | | | | | 0 | | |
基于股份的薪酬
|
| | | | 0 | | | | | | 174 | | |
Total
|
| | | | 0 | | | | | | 174 | | |
|
Name
|
| |
Grant Date
|
| |
Number of Ordinary
Shares Underlying Warrants(2) |
| |
Warrant
Exercise Price DKK |
| |
Warrant
Expiration Date |
| ||||||
Marianne Søgaard (Chairperson)(1)
|
| | 2018/2019/2020 | | | | | 94,320 | | | | | | 1 | | | |
December 31, 2036
|
|
Helen M. Boudreau (director)
|
| | 2020 | | | | | 5,436 | | | | | | 1 | | | |
December 31, 2036
|
|
Jo Ann Suzich (director)
|
| | 2019/2020 | | | | | 10,260 | | | | | | 1 | | | |
December 31, 2036
|
|
Roberto Prego (director)
|
| | 2017/2018/2020 | | | | | 27,036 | | | | | | 1 | | | |
December 31, 2036
|
|
Steven Projan (director)
|
| | 2018/2019/2020 | | | | | 42,048 | | | | | | 1 | | | |
December 31, 2036
|
|
Kim Bjoernstrup (director)(1)
|
| | — | | | | | 0 | | | | | | — | | | | — | |
Lars Staal Wegner (CEO)
|
| | 2016/2017/2018/2020 | | | | | 852,264 | | | | | | 1 | | | |
December 31, 2036
|
|
Niels Iverson Møller (CBO)
|
| | — | | | | | 0 | | | | | | — | | | | — | |
Andreas Holm Mattson (CIO)
|
| | — | | | | | 0 | | | | | | — | | | | — | |
Glenn S. Vraniak (CFO)
|
| | 2019 | | | | | 150,660 | | | | | | 1 | | | |
December 31, 2036
|
|
Position
|
| |
Retainer
|
| |||
Board Member
|
| | | $ | 40,000 | | |
Board Chairperson
|
| | | $ | 80,000 | | |
Audit Committee Chair
|
| | | $ | 15,000 | | |
薪酬委员会主席
|
| | | $ | 4,000 | | |
提名和公司治理委员会主席
|
| | | $ | 4,000 | | |
Audit Committee Member
|
| | | $ | 4,000 | | |
薪酬委员会成员
|
| | | $ | 4,000 | | |
提名和公司治理委员会主席
|
| | | $ | 4,000 | | |
Name of Beneficial Owner
|
| |
实益拥有的股份
before The Offering |
| |
实益拥有的股份
after The Offering |
| |
Percent of Shares
Beneficially Owned Assuming Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| |||||||||||||||||||||
| | |
Number
|
| |
Percent
|
| |
Number
|
| |
Percent
|
| | | | | | | ||||||||||||
5%或更大股东 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
NIMedical Holding ApS(1)
|
| | | | 4,292,604 | | | | | | 26.50 | | | | | | 4,292,604 | | | | | | 22.36 | | | | | | 21.85 | | |
Mattsson Holding af 2008 ApS(2)
|
| | | | 4,163,832 | | | | | | 25.70 | | | | | | 4,163,832 | | | | | | 21.69 | | | | | | 21.19 | | |
Punga Punga C.V.(3)
|
| | | | 826,560 | | | | | | 5.10 | | | | | | 826,560 | | | | | | 4.31 | | | | | | 4.21 | | |
执行管理 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Lars Staal Wegner(4)
|
| | | | 182,124 | | | | | | 1.12 | | | | | | 182,124 | | | | | | * | | | | | | * | | |
Niels Iverson Møller(1)
|
| | | | 4,292,604 | | | | | | 26.50 | | | | | | 4,292,604 | | | | | | 22.36 | | | | | | 21.85 | | |
Andreas Holm Mattson(2)
|
| | | | 4,163,832 | | | | | | 25.70 | | | | | | 4,163,832 | | | | | | 21.69 | | | | | | 21.19 | | |
Glenn S. Vraniak
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Directors | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Helen M. Boudreau
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Roberto Prego
|
| | | | 310,248 | | | | | | 1.92 | | | | | | 310,248 | | | | | | 1.62 | | | | | | 1.58 | | |
Steven Projan
|
| | | | 27,288 | | | | | | * | | | | | | 27,288 | | | | | | * | | | | | | * | | |
Jo Ann Suzich
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Marianne Søgaard
|
| | | | 41,652 | | | | | | * | | | | | | 41,652 | | | | | | * | | | | | | * | | |
所有现任董事和执行管理层,作为一个小组(9人)
|
| | | | 9,017,748 | | | | | | 55.67 | | | | | | 9,017,748 | | | | | | 46.97 | | | | | | 45.89 | | |
Date
|
| |
Transaction
|
| |
Share Capital
After Transaction |
| |
Price
Per share (DKK) |
| ||||||
August 2008
|
| | Formation (Nominal DKK 1) | | | | | 250,000 | | | | | | 1.00 | | |
March 2014
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 268,148 | | | | | | 120.00 | | |
December 2014
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 316,751 | | | | | | 178.22 | | |
December 2015
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 336,549 | | | | | | 435.76 | | |
March 2016
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 342,880 | | | | | | 432.12 | | |
September 2017
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 358,806 | | | | | | 1,034.75 | | |
March 2019
|
| | 转移储备(名义1丹麦克朗) | | | | | 717,612 | | | | | | 1.00 | | |
July 2019
|
| |
现金出资和债务转换
(Nominal DKK 1) |
| | | | 836,994 | | | | | | 914.71(avg) | | |
December 2019
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 843,564 | | | | | | 1,037.50 | | |
September 2020
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 884,974 | | | | | | 1,002.90 | | |
October 2020
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 899,926 | | | | | | 1,008.45 | | |
January 2021
|
| | Share split 2-for-1 (Nominal DKK 1) | | | | | 899,926 | | | | | | — | | |
January 2021
|
| |
1送17(名义1丹麦克朗)红股发行
|
| | | | 16,198,668 | | | | | | — | | |
Grant Date
|
| |
Vesting Period
|
| |
Expiration Date
|
| |
Exercise Price
|
| |
Number of Warrants
|
|
December 19, 2016
|
| |
Upon an IPO Event
|
| |
December 31, 2036
|
| |
DKK 1.0
|
| |
758,448
|
|
December 10, 2017
|
| |
Upon an IPO Event
|
| |
December 31, 2036
|
| |
DKK 1.0
|
| |
632,700
|
|
Grant Date
|
| |
Vesting Period
|
| |
Expiration Date
|
| |
Exercise Price
|
| |
Number of Warrants
|
|
December 19, 2017
|
| |
Upon an IPO Event
|
| |
December 31, 2036
|
| |
DKK 1.0
|
| |
141,804
|
|
December 17, 2020
|
| |
Upon Exit/1/36 per month
|
| |
December 31, 2036
|
| |
DKK 1.0
|
| |
757,620
|
|
未经锻炼即失效或作废
|
| | | | | | | | | | |
(62,316)
|
|
| | | | | | | | | | | |
2,228,256
|
|
|
存取款人员
股票或美国存托股份持有人必须支付: |
| |
For:
|
|
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs) | | |
美国存托凭证的发行,包括因股份、权利或其他财产的分配而产生的发行
为取款目的取消美国存托凭证,包括存款协议终止的情况
|
|
$.05 (or less) per ADS | | | 对美国存托股份持有者的任何现金分配 | |
如果分发给您的证券是股票,并且这些股票是为发行美国存托凭证而存放的,则应支付的费用相当于该费用 | | | 由托管人分配给美国存托股份持有人的分配给已存放证券(包括权利)持有人的证券的分配 | |
每历年每个美国存托股份0.05美元(或更少) | | | 托管服务 | |
注册费或转让费 | | | 当您存入或提取股票时,我们股票登记簿上的股票以托管人或其代理人的名义进行转让和登记 | |
托管人的费用 | | |
电报和传真传输(如果存款协议中明确规定)
将外币兑换成美元
|
|
托管人或托管人必须为任何美国存托凭证或股票支付的税款和其他政府费用,如股票转让税、印花税或预扣税 | | | As necessary | |
托管人或其代理人为已交存证券支付的任何费用 | | | As necessary | |
Underwriter
|
| |
Number of
ADSs |
| |||
Oppenheimer & Co. Inc.
|
| | | | 2,100,000 | | |
Ladenburg Thalmann & Co. Inc.
|
| | | | 900,000 | | |
Total
|
| | | | 3,000,000 | | |
| | |
Per ADS
|
| |
Total
Without Exercise of Over- Allotment Option |
| |
Total With
Full Exercise of Over- Allotment Option |
| |||||||||
Public offering price
|
| | | $ | 10.00 | | | | | $ | 30,000,000 | | | | | $ | 34,500,000 | | |
承保折扣和佣金
|
| | | $ | 0.70 | | | | | $ | 2,100,000 | | | | | $ | 2,415,000 | | |
未扣除费用的收益给我们
|
| | | $ | 9.30 | | | | | $ | 27,900,000 | | | | | $ | 32,085,000 | | |
| | 就本条文而言,就任何相关国家的任何美国存托凭证而言,“向公众要约”一词是指以任何形式及以任何方式就要约条款及任何拟要约的美国存托凭证向公众传达,以使投资者能够决定购买或认购任何美国存托凭证,而“招股章程规例”一词是指条例(EU)2017/1129。 | | |
| | 关于联合王国,对《招股说明书条例》的提及包括《招股说明书条例》,因为根据《2018年欧盟(退出)法》,《招股说明书条例》是英国国内法的一部分。 | | |
Expenses
|
| |
Amount
|
| |||
SEC registration fee
|
| | | $ | 4,141 | | |
纳斯达克资本市场准入和上市费
|
| | | | 55,000 | | |
FINRA filing fee
|
| | | | 5,675 | | |
印刷费和雕刻费
|
| | | | 370,000 | | |
Legal fees and expenses
|
| | | | 1,000,000 | | |
会计费和费用
|
| | | | 700,000 | | |
Miscellaneous costs
|
| | | | 60,000 | | |
Total
|
| | | $ | 2,194,816 | | |
| | |
Page
|
| |||
经审计的财务报表: | | | | | | | |
独立注册会计师事务所报告
|
| | | | F-2 | | |
Financial Statements:
|
| | | | | | |
截至2018年12月31日和2019年12月31日止年度的全面亏损报表
|
| | | | F-3 | | |
截至2018年1月1日和2018年12月31日及2019年12月31日的财务状况报表
|
| | | | F-4 | | |
截至2018年和2019年12月31日止年度的权益变动表
|
| | | | F-5 | | |
截至2018年12月31日和2019年12月31日的年度现金流量表
|
| | | | F-6 | | |
财务报表附注
|
| | | | F-7 | | |
|
截至2020年和2019年9月30日的9个月未经审计的中期综合综合全面亏损报表
|
| | | | F-40 | | |
|
截至2020年9月30日和2019年12月31日未经审计的中期简明财务状况报表
|
| | | | F-41 | | |
|
前九个月未经审计的中期简明权益变动表
Ended September 30, 2020 and 2019 |
| | | | F-42 | | |
|
截至9个月的未经审计的中期现金流量简明合并报表
September 30, 2020 and 2019 |
| | | | F-43 | | |
|
未经审计的中期简明合并财务报表附注
|
| | | | F-44 | | |
| | | | | |
Years Ended December 31,
|
| |||||||||
| | |
Note
|
| |
2018
|
| |
2019
|
| ||||||
| | | | | |
(单位为千美元,每股除外)
|
| |||||||||
Operating expenses: | | | | | | | | | | | | | | | | |
研发
|
| |
6
|
| | | $ | 3,729 | | | | | $ | 8,216 | | |
一般和行政
|
| |
6
|
| | | | 1,898 | | | | | | 2,647 | | |
总运营费用
|
| | | | | | | 5,627 | | | | | | 10,863 | | |
Operating loss
|
| | | | | | | (5,627) | | | | | | (10,863) | | |
Finance income
|
| |
9
|
| | | | 76 | | | | | | 65 | | |
Finance expenses
|
| |
9
|
| | | | (719) | | | | | | (1,222) | | |
Net loss before tax
|
| | | | | | | (6,270) | | | | | | (12,020) | | |
Income taxes
|
| |
10
|
| | | | 735 | | | | | | 825 | | |
Net loss for the year
|
| | | | | | $ | (5,535) | | | | | $ | (11,195) | | |
Evaxion Biotech A/S股东应占净亏损
|
| | | | | | $ | (5,535) | | | | | $ | (11,195) | | |
后续期间不重新分类为损益的其他全面收入(税后净额):
|
| | | | | | | | | | | | | | | |
货币折算成提示货币的汇兑差额
|
| |
17
|
| | | | (15) | | | | | | 2 | | |
本年度其他综合亏损,税后净额
|
| | | | | | $ | (15) | | | | | $ | 2 | | |
全面亏损
|
| | | | | | $ | (5,550) | | | | | $ | (11,193) | | |
Evaxion Biotech A/S股东应占全面亏损总额
|
| | | | | | $ | (5,550) | | | | | $ | (11,193) | | |
Loss per share – basic and diluted
|
| |
11
|
| | | $ | (0.43) | | | | | $ | (0.81) | | |
| | | | | |
January 1,
2018 |
| |
December 31,
|
| ||||||||||||
| | |
Note
|
| |
2018
|
| |
2019
|
| ||||||||||||
| | | | | |
(USD in thousands)
|
| |||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | |
Non-current assets | | | | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备
|
| |
12
|
| | | $ | 179 | | | | | $ | 112 | | | | | $ | 101 | | |
Leasehold deposits
|
| |
16
|
| | | | 32 | | | | | | 18 | | | | | | 25 | | |
非流动资产合计
|
| | | | | | | 211 | | | | | | 130 | | | | | | 126 | | |
Current assets | | | | | | | | | | | | | | | | | | | | | | |
Receivables
|
| |
13
|
| | | | 680 | | | | | | 238 | | | | | | 575 | | |
未缴出资应收款项
|
| | | | | | | 1,129 | | | | | | – | | | | | | – | | |
Tax receivables
|
| |
10
|
| | | | 461 | | | | | | 712 | | | | | | 824 | | |
现金和现金等价物
|
| |
15
|
| | | | 468 | | | | | | 7,433 | | | | | | 9,559 | | |
Total current assets
|
| | | | | | | 2,738 | | | | | | 8,383 | | | | | | 10,958 | | |
TOTAL ASSETS
|
| | | | | | $ | 2,949 | | | | | $ | 8,513 | | | | | $ | 11,084 | | |
权益和负债 | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| |
17
|
| | | $ | 2,113 | | | | | $ | 2,113 | | | | | $ | 2,481 | | |
Other reserves
|
| |
17
|
| | | | 3,950 | | | | | | 3,935 | | | | | | 22,693 | | |
Accumulated deficit
|
| |
17
|
| | | | (3,513) | | | | | | (6,979) | | | | | | (15,812) | | |
Total equity
|
| | | | | | | 2,550 | | | | | | (931) | | | | | | 9,362 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | | | | |
Lease liabilities
|
| |
16
|
| | | | 96 | | | | | | 24 | | | | | | – | | |
非流动负债合计
|
| | | | | | | 96 | | | | | | 24 | | | | | | – | | |
流动负债 | | | | | | | | | | | | | | | | | | | | | | |
可转换债务工具
|
| |
18
|
| | | | – | | | | | | 8,569 | | | | | | – | | |
Lease liabilities
|
| |
16
|
| | | | 66 | | | | | | 75 | | | | | | 36 | | |
Trade payables
|
| | | | | | | 59 | | | | | | 139 | | | | | | 646 | | |
Other payables
|
| |
14
|
| | | | 178 | | | | | | 637 | | | | | | 1,040 | | |
流动负债总额
|
| | | | | | | 303 | | | | | | 9,420 | | | | | | 1,722 | | |
Total liabilities
|
| | | | | | | 399 | | | | | | 9,444 | | | | | | 1,722 | | |
权益和负债合计
|
| | | | | | $ | 2,949 | | | | | $ | 8,513 | | | | | $ | 11,084 | | |
| | | | | | | | | | | |
Other reserves
|
| | | | | | | | | | | | | |||||||||
| | |
Note
|
| |
Share
capital |
| |
Share
premium |
| |
Foreign
currency translation reserve |
| |
Accumulated
deficit |
| |
Total equity
|
| |||||||||||||||
| | | | | |
(USD in thousands)
|
| |||||||||||||||||||||||||||
Equity at January 1, 2018
|
| | | | | | $ | 117 | | | | | $ | 6,102 | | | | | $ | (156) | | | | | $ | (3,513) | | | | | $ | 2,550 | | |
Bonus share issuance
|
| |
21
|
| | | | 1,996 | | | | | | (1,996) | | | | | | – | | | | | | – | | | | | | – | | |
Equity at January 1, 2018
|
| | | | | | | 2,113 | | | | | | 4,106 | | | | | | (156) | | | | | | (3,513) | | | | | | 2,550 | | |
Net loss for the year
|
| | | | | | | – | | | | | | – | | | | | | – | | | | | | (5,535) | | | | | | (5,535) | | |
其他综合收益
|
| |
17
|
| | | | – | | | | | | – | | | | | | (15) | | | | | | – | | | | | | (15) | | |
基于股份的薪酬费用
|
| |
8
|
| | | | – | | | | | | – | | | | | | – | | | | | | 2,069 | | | | | | 2,069 | | |
Equity at December 31, 2018
|
| | | | | | $ | 2,113 | | | | | $ | 4,106 | | | | | $ | (171) | | | | | $ | (6,979) | | | | | $ | (931) | | |
Net loss for the year
|
| | | | | | | – | | | | | | – | | | | | | – | | | | | | (11,195) | | | | | | (11,195) | | |
其他综合收益
|
| |
17
|
| | | | – | | | | | | – | | | | | | 2 | | | | | | – | | | | | | 2 | | |
基于股份的薪酬费用
|
| |
8
|
| | | | – | | | | | | – | | | | | | – | | | | | | 2,362 | | | | | | 2,362 | | |
发行股票换取现金
|
| |
17
|
| | | | 181 | | | | | | 9,261 | | | | | | – | | | | | | – | | | | | | 9,442 | | |
Transaction costs
|
| |
17
|
| | | | – | | | | | | (13) | | | | | | – | | | | | | – | | | | | | (13) | | |
可转换债务工具结算
|
| |
18
|
| | | | 187 | | | | | | 9,508 | | | | | | – | | | | | | – | | | | | | 9,695 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Equity at December 31, 2019
|
| | | | | | $ | 2,481 | | | | | $ | 22,862 | | | | | $ | (169) | | | | | $ | (15,812) | | | | | $ | 9,362 | | |
| | | | | |
Years Ended December 31,
|
| |||||||||
| | |
Note
|
| |
2018
|
| |
2019
|
| ||||||
| | | | | |
(USD in thousands)
|
| |||||||||
经营活动: | | | | | | | | | | | | | | | | |
Net loss for the year
|
| | | | | | $ | (5,535) | | | | | $ | (11,195) | | |
非现金项目调整
|
| |
15
|
| | | | 2,123 | | | | | | 2,945 | | |
非流动金融资产 - 租赁存款变动
|
| | | | | | | 13 | | | | | | (7) | | |
Interest received
|
| | | | | | | 2 | | | | | | 9 | | |
Interest paid
|
| | | | | | | (15) | | | | | | (39) | | |
Income taxes received
|
| | | | | | | 453 | | | | | | 688 | | |
营运资金变动前的经营活动现金流
|
| | | | | | | (2,959) | | | | | | (7,599) | | |
营运资金变动产生的现金流: | | | | | | | | | | | | | | | | |
净营运资金变动
|
| |
15
|
| | | | 981 | | | | | | 573 | | |
经营活动中使用的净现金
|
| | | | | | | (1,978) | | | | | | (7,026) | | |
投资活动: | | | | | | | | | | | | | | | | |
购置房产、厂房和设备
|
| |
12
|
| | | | (7) | | | | | | (61) | | |
投资活动中使用的净现金
|
| | | | | | | (7) | | | | | | (61) | | |
融资活动: | | | | | | | | | | | | | | | | |
股票发行收益
|
| |
17
|
| | | | 1,092 | | | | | | 9,442 | | |
与发行股票相关的交易成本
|
| | | | | | | – | | | | | | (13) | | |
发行可转换债务工具所得收益
|
| |
15
|
| | | | 7,998 | | | | | | 152 | | |
Leasing installments
|
| |
15, 16
|
| | | | (63) | | | | | | (73) | | |
融资活动提供的现金净额
|
| | | | | | | 9,027 | | | | | | 9,508 | | |
现金和现金等价物净增长
|
| | | | | | | 7,042 | | | | | | 2,421 | | |
年初现金和现金等价物
|
| |
15
|
| | | | 468 | | | | | | 7,433 | | |
现金和现金等价物的汇率调整
|
| | | | | | | (77) | | | | | | (295) | | |
现金和现金等价物,年终
|
| |
15
|
| | | $ | 7,433 | | | | | $ | 9,559 | | |
Assets
|
| |
Useful life
|
|
Properties | | | 资产的租赁期限和使用寿命较短 | |
Other equipment | | | 3 – 6 years | |
| | |
Ref.
|
| |
As most recently
reported at January 1, 2018 (Local GAAP) |
| |
IFRS
conversion |
| |
As adjusted at
January 1, 2018 (IFRS) |
| ||||||||||||
| | | | | | | | |
(USD in thousands)
|
| |||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备
|
| | | | 1 | | | | | $ | 21 | | | | | $ | 158 | | | | | $ | 179 | | |
Leasehold deposits
|
| | | | | | | | | | 32 | | | | | | – | | | | | | 32 | | |
非流动资产合计 | | | | | | | | | | | 53 | | | | | | 158 | | | | | | 211 | | |
Receivables
|
| | | | | | | | | | 680 | | | | | | – | | | | | | 680 | | |
未缴出资应收款项
|
| | | | | | | | | | 1,129 | | | | | | – | | | | | | 1,129 | | |
Tax receivables
|
| | | | | | | | | | 461 | | | | | | – | | | | | | 461 | | |
现金和现金等价物
|
| | | | | | | | | | 468 | | | | | | – | | | | | | 468 | | |
Total current assets
|
| | | | | | | | | | 2,738 | | | | | | – | | | | | | 2,738 | | |
TOTAL ASSETS
|
| | | | | | | | | $ | 2,791 | | | | | $ | 158 | | | | | $ | 2,949 | | |
权益和负债 | | | | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | | | | | | $ | 117 | | | | | $ | – | | | | | $ | 117 | | |
Other reserves
|
| | | | | | | | | | 5,946 | | | | | | – | | | | | | 5,946 | | |
Accumulated deficit
|
| | | | 1 | | | | | | (3,509) | | | | | | (4) | | | | | | (3,513) | | |
Total equity
|
| | | | | | | | | | 2,554 | | | | | | (4) | | | | | | 2,550 | | |
Lease liabilities
|
| | | | 1 | | | | | | – | | | | | | 96 | | | | | | 96 | | |
Total current assets
|
| | | | | | | | | | – | | | | | | 96 | | | | | | 96 | | |
Lease liabilities
|
| | | | 1 | | | | | | – | | | | | | 66 | | | | | | 66 | | |
Trade payables
|
| | | | | | | | | | 59 | | | | | | – | | | | | | 59 | | |
Other payables
|
| | | | | | | | | | 178 | | | | | | – | | | | | | 178 | | |
流动负债总额
|
| | | | | | | | | | 237 | | | | | | 66 | | | | | | 303 | | |
Total liabilities
|
| | | | | | | | | | 237 | | | | | | 162 | | | | | | 399 | | |
权益和负债合计
|
| | | | | | | | | $ | 2,791 | | | | | $ | 158 | | | | | $ | 2,949 | | |
| | |
Ref.
|
| |
As most recently
reported at December 31, 2018 (Local GAAP) |
| |
IFRS
conversion |
| |
As adjusted at
December 31, 2018 (IFRS) |
| |||||||||
| | | | | |
(USD in thousands)
|
| |||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备
|
| |
1
|
| | | $ | 20 | | | | | $ | 92 | | | | | $ | 112 | | |
Leasehold deposits
|
| | | | | | | 18 | | | | | | – | | | | | | 18 | | |
非流动资产合计
|
| | | | | | | 38 | | | | | | 92 | | | | | | 130 | | |
Receivables | | | | | | | | 238 | | | | | | – | | | | | | 238 | | |
Tax receivables
|
| | | | | | | 712 | | | | | | – | | | | | | 712 | | |
现金和现金等价物
|
| | | | | | | 7,433 | | | | | | – | | | | | | 7,433 | | |
Total current assets
|
| | | | | |
|
8,383
|
| | | | | – | | | | |
|
8,383
|
| |
TOTAL ASSETS
|
| | | | | | $ | 8,421 | | | | | $ | 92 | | | | | $ | 8,513 | | |
|
| | |
Ref.
|
| |
As most recently
reported at December 31, 2018 (Local GAAP) |
| |
IFRS
conversion |
| |
As adjusted at
December 31, 2018 (IFRS) |
| |||||||||
| | | | | |
(USD in thousands)
|
| |||||||||||||||
权益和负债 | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | | | $ | 2,113 | | | | | $ | – | | | | | $ | 2,113 | | |
Other reserves
|
| |
2
|
| | | | 9,930 | | | | | | (5,995) | | | | | | 3,935 | | |
Accumulated deficit
|
| |
1, 2, 3
|
| | | | (6,300) | | | | | | (679) | | | | | | (6,979) | | |
Total equity
|
| | | | | | | 5,743 | | | | | | (6,674) | | | | | | (931) | | |
Lease liabilities
|
| | | | | | | – | | | | | | 24 | | | | | | 24 | | |
非流动负债合计
|
| |
1
|
| | | | – | | | | |
|
24
|
| | | |
|
24
|
| |
可转换债务工具
|
| |
2
|
| | | | 1,902 | | | | | | 6,667 | | | | | | 8,569 | | |
Lease liabilities
|
| |
1
|
| | | | – | | | | | | 75 | | | | | | 75 | | |
Trade payables
|
| | | | | | | 139 | | | | | | – | | | | | | 139 | | |
Other payables
|
| | | | | | | 637 | | | | | | – | | | | | | 637 | | |
流动负债总额
|
| | | | | | | 2,678 | | | | | | 6,742 | | | | | | 9,420 | | |
Total liabilities
|
| | | | | | | 2,678 | | | | | | 6,766 | | | | | | 9,444 | | |
权益和负债合计
|
| | | | | | $ | 8,421 | | | | | $ | 92 | | | | | $ | 8,513 | | |
|
| | |
Ref.
|
| |
As most recently
reported for the year ended December 31, 2018 (Local GAAP) |
| |
IFRS
conversion |
| |
As adjusted for
the year ended December 31, 2018 (IFRS) |
| | | |||||||||||||
| | | | | |
(USD in thousands)
|
| | | | | | | |||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | ||||
Gross loss
|
| |
4
|
| | | $ | (1,592) | | | | | $ | 1,592 | | | | | $ | – | | | | | ||||
Staff costs
|
| |
4
|
| | | | (1,956) | | | | | | 1,956 | | | | | | – | | | | | ||||
折旧、摊销和减值损失
|
| |
4
|
| | | | (10) | | | | | | 10 | | | | | | – | | | | | ||||
研发
|
| |
3, 4
|
| | | | – | | | | | | (3,729) | | | | | | (3,729) | | | | | ||||
一般和行政
|
| |
3, 4
|
| | | | – | | | | | | (1,898) | | | | | | (1,898) | | | | | ||||
Operating loss
|
| | | | | | | (3,558) | | | | | | (2,069) | | | | | | (5,627) | | | | | ||||
Financial income
|
| | | | | | | 76 | | | | | | – | | | | | | 76 | | | | | ||||
Financial expenses
|
| |
1, 2
|
| | | | (107) | | | | | | (612) | | | | | | (719) | | | | | ||||
Net loss before tax
|
| | | | | | | (3,589) | | | | | | (2,681) | | | | | | (6,270) | | | | | ||||
Income tax
|
| | | | | | | 735 | | | | | | – | | | | | | 735 | | | | | ||||
Net loss for the year
|
| | | | | | $ | (2,854) | | | | | $ | (2,681) | | | | | $ | (5,535) | | | | | ||||
Evaxion股东应占净亏损
Biotech A/S |
| | | | | | $ | (2,854) | | | | | $ | (2,681) | | | | | $ | (5,535) | | | | | ||||
|
| | |
Ref.
|
| |
As most recently
reported for the year ended December 31, 2018 (Local GAAP) |
| |
IFRS
conversion |
| |
As adjusted for
the year ended December 31, 2018 (IFRS) |
| | | |||||||||||||
| | | | | |
(USD in thousands)
|
| | | | | | | |||||||||||||||
后续期间不重新分类为损益的其他全面收入(税后净额):
|
| | | | | | | | | | | | | | | | | | | | | | | | ||||
货币折算成提示货币的汇兑差额
|
| | | | | | | 68 | | | | | | (83) | | | | | | (15) | | | | | ||||
全面亏损
|
| | | | | | $ | (2,786) | | | | | $ | (2,764) | | | | | $ | (5,550) | | | | | ||||
Evaxion Biotech A/S股东应占全面亏损总额
|
| | | | | | $ | (2,786) | | | | | $ | (2,764) | | | | | $ | (5,550) | | | | | ||||
|
| | |
January 1, 2018
|
| |||||||||||||||||||||||||||||||||
(USD in thousands)
|
| |
Carrying
amount |
| |
Contractual
cash flows |
| |
year
|
| |
1 – 5
years |
| |
>5
years |
| |
Total
|
| ||||||||||||||||||
Lease liabilities
|
| | | $ | 162 | | | | | $ | 198 | | | | | $ | 68 | | | | | $ | 130 | | | | | $ | – | | | | | $ | 198 | | |
Trade payables
|
| | | | 59 | | | | | | 59 | | | | | | 59 | | | | | | – | | | | | | – | | | | | | 59 | | |
Other payables
|
| | | | 19 | | | | | | 19 | | | | | | 19 | | | | | | – | | | | | | – | | | | | | 19 | | |
Total
|
| | | $ | 240 | | | | | $ | 276 | | | | | $ | 146 | | | | | $ | 130 | | | | | $ | – | | | | | $ | 276 | | |
|
| | |
December 31, 2018
|
| |||||||||||||||||||||||||||||||||
(USD in thousands)
|
| |
Carrying
amount |
| |
Contractual
cash flows |
| |
year
|
| |
1 – 5
years |
| |
>5
years |
| |
Total
|
| ||||||||||||||||||
可转换债务工具(1)
|
| | | $ | 8,569 | | | | | $ | 2,132 | | | | | $ | 2,132 | | | | | $ | — | | | | | $ | — | | | | | $ | 2,132 | | |
Lease liabilities
|
| | | | 99 | | | | | | 130 | | | | | | 75 | | | | | | 55 | | | | | | | | | | | | 130 | | |
Trade payables
|
| | | | 139 | | | | | | 139 | | | | | | 139 | | | | | | — | | | | | | — | | | | | | 139 | | |
Other payables
|
| | | | 214 | | | | | | 214 | | | | | | 214 | | | | | | — | | | | | | — | | | | | | 214 | | |
Total
|
| | | $ | 9,021 | | | | | $ | 2,615 | | | | | $ | 2,560 | | | | | $ | 55 | | | | | $ | — | | | | | $ | 2,615 | | |
| | |
December 31, 2019
|
| |||||||||||||||||||||||||||||||||
(USD in thousands)
|
| |
Carrying
amount |
| |
Contractual
cash flows |
| |
year
|
| |
1 – 5
years |
| |
>5
years |
| |
Total
|
| ||||||||||||||||||
Lease liabilities
|
| | | $ | 36 | | | | | $ | 55 | | | | | $ | 55 | | | | | $ | — | | | | | $ | — | | | | | $ | 55 | | |
Trade payables
|
| | | | 646 | | | | | | 646 | | | | | | 646 | | | | | | — | | | | | | — | | | | | | 646 | | |
Other payables
|
| | | | 177 | | | | | | 177 | | | | | | 177 | | | | | | — | | | | | | — | | | | | | 177 | | |
Total
|
| | | $ | 859 | | | | | $ | 878 | | | | | $ | 878 | | | | | $ | — | | | | | $ | — | | | | | $ | 878 | | |
| | |
December 31, 2018
|
| |||||||||||||||||||||
(USD in thousands)
|
| |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Aggregate
Fair Value |
| ||||||||||||
Liabilities: | | | | | | | | | | | | | | | | | | | | | | | | | |
可转换债务工具
|
| | | $ | – | | | | | $ | – | | | | | $ | 8,569 | | | | | $ | 8,569 | | |
Total liabilities
|
| | | $ | – | | | | | $ | – | | | | | $ | 8,569 | | | | | $ | 8,569 | | |
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
员工工资和福利支出,不包括基于股份的薪酬
|
| | | $ | (1,756) | | | | | $ | (2,586) | | |
基于股份的薪酬费用
|
| | | | (896) | | | | | | (1,021) | | |
Depreciation
|
| | | | (59) | | | | | | (65) | | |
External expenses
|
| | | | (1,018) | | | | | | (4,544) | | |
研发费用总额
|
| | | $ | (3,729) | | | | | $ | (8,216) | | |
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
员工工资和福利支出,不包括基于股份的薪酬
|
| | | $ | (190) | | | | | $ | (517) | | |
基于股份的薪酬费用
|
| | | | (1,173) | | | | | | (1,341) | | |
Professional fees
|
| | | | (520) | | | | | | (773) | | |
Depreciation
|
| | | | (15) | | | | | | (16) | | |
一般和行政费用合计
|
| | | $ | (1,898) | | | | | $ | (2,647) | | |
| | |
Years Ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
全职员工平均人数
|
| | | | 18 | | | | | | 25 | | |
期末按国家分列的雇员(包括顾问)人数: | | | | | | | | | | | | | |
Denmark
|
| | | | 20 | | | | | | 36 | | |
期末包括顾问在内的员工总数
|
| | | | 20 | | | | | | 36 | | |
|
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
Wages and salaries
|
| | | $ | 1,733 | | | | | $ | 2,819 | | |
基于股份的薪酬费用
|
| | | | 2,069 | | | | | | 2,362 | | |
已定义的缴费计划
|
| | | | 70 | | | | | | 96 | | |
其他社会保障费用
|
| | | | 10 | | | | | | 12 | | |
Other staff expenses
|
| | | | 133 | | | | | | 176 | | |
Total
|
| | | $ | 4,015 | | | | | $ | 5,465 | | |
|
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
员工总成本分类为: | | | | | | | | | | | | | |
研发费用
|
| | | $ | 2,652 | | | | | $ | 3,607 | | |
一般和行政费用
|
| | | | 1,363 | | | | | | 1,858 | | |
Total
|
| | | $ | 4,015 | | | | | $ | 5,465 | | |
|
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
非管理层员工福利支出分类为: | | | | | | | | | | | | | |
研发费用
|
| | | $ | 1,686 | | | | | $ | 2,590 | | |
一般和行政费用
|
| | | | 26 | | | | | | 668 | | |
Total
|
| | | $ | 1,712 | | | | | $ | 3,258 | | |
| | |
Year Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
高管薪酬: | | | | | | | | | | | | | |
Wages and salaries
|
| | | $ | 621 | | | | | $ | 900 | | |
基于股份的薪酬费用
|
| | | | 1,157 | | | | | | 956 | | |
Total
|
| | | | 1,778 | | | | | | 1,856 | | |
董事会薪酬: | | | | | | | | | | | | | |
基于股份的薪酬费用
|
| | | | 525 | | | | | | 351 | | |
Total
|
| | | | 525 | | | | | | 351 | | |
董事会和执行管理层的薪酬分类为:
|
| | | | | | | | | | | | |
研发费用
|
| | | | 965 | | | | | | 1,017 | | |
一般和行政费用
|
| | | | 1,338 | | | | | | 1,190 | | |
Total
|
| | | $ | 2,303 | | | | | $ | 2,207 | | |
|
| | |
Number
of warrants |
| |
Weighted
Average Exercise Price/Share (DKK) |
| |
Weighted
Average Remaining Contractual Life (years) |
| ||||||
Warrants granted as at January 1, 2018*
|
| | | | 1,481,796 | | | |
DKK 1
|
| | | | 19 | | |
Warrants granted**
|
| | | | 192,528 | | | |
1
|
| | | | 18 | | |
Warrants granted as at December 31, 2018
|
| | | | 1,674,324 | | | |
1
|
| | | | 18 | | |
Warrants granted**
|
| | | | 257,832 | | | |
1
|
| | | | 17 | | |
Warrants granted as at December 31, 2019
|
| | | | 1,932,156 | | | |
DKK 1
|
| | | | 17 | | |
于2018年12月31日可行使的认股权证
|
| | | | – | | | |
DKK 1
|
| | | | – | | |
于2019年12月31日可行使的认股权证
|
| | | | – | | | |
DKK 1
|
| | | | – | | |
Participants
|
| |
Number of
warrants |
| |
Estimated
fair value |
| |
Vesting Term
|
| |
Exercise Price
(DKK) |
| |||||||||
Employees
|
| | | | 63,360 | | | | | $ | 60万 | | | |
3 years
|
| | | | 1 | | |
科学顾问委员会
|
| | | | 22,860 | | | | | $ | 20万 | | | |
Immediate
|
| | | | 1 | | |
Board of Directors
|
| | | | 40,752 | | | | | $ | 40万 | | | |
Immediate
|
| | | | 1 | | |
| | |
Years Ended
December 31, |
| | |||||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| | ||||||||
研发费用
|
| | | $ | 896 | | | | | $ | 1,021 | | | | ||
一般和行政费用
|
| | | | 1,173 | | | | | | 1,341 | | | | ||
Total
|
| | | $ | 2,069 | | | | | $ | 2,362 | | | | | |
Outstanding program
|
| |
Per warrant
weighted average grant date fair value (DKK) |
| |
Number of
warrants outstanding |
| |
Average
exercise price per warrant (DKK) |
| |
Remaining
term to maturity (years) |
| ||||||||||||
Grant (December 2016)
|
| | | | 20.91 | | | | | | 712,332 | | | | | | 1 | | | | | | 18 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 13,896 | | | | | | 1 | | | | | | 18 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 617,184 | | | | | | 1 | | | | | | 18 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 138,384 | | | | | | 1 | | | | | | 18 | | |
Granted (during 2018)**
|
| | | | 37.05 | | | | | | 192,528 | | | | | | 1 | | | | | | 18 | | |
Granted at December 31, 2018
|
| | | | | | | | | | 1,674,324 | | | | | | 1 | | | | | | 18 | | |
可于2018年12月31日执行的认股权证
|
| | | | | | | | | | – | | | | | | 1 | | | | | | 17 | | |
|
Outstanding program
|
| |
Per warrant
weighted average grant date fair value (DKK) |
| |
Number of
warrants outstanding |
| |
Average
exercise price per warrant (DKK) |
| |
Remaining
term to maturity (years) |
| ||||||||||||
Grant (December 2016)
|
| | | | 20.91 | | | | | | 712,332 | | | | | | 1 | | | | | | 17 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 13,896 | | | | | | 1 | | | | | | 17 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 617,184 | | | | | | 1 | | | | | | 17 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 138,384 | | | | | | 1 | | | | | | 17 | | |
Grant (during 2018)(1)**
|
| | | | 37.05 | | | | | | 192,528 | | | | | | 1 | | | | | | 17 | | |
Grant (January 2019)(1)**
|
| | | | 37.05 | | | | | | 45,216 | | | | | | 1 | | | | | | 17 | | |
Grant (February 2019)**
|
| | | | 42.57 | | | | | | 7,956 | | | | | | 1 | | | | | | 17 | | |
Grant (September 2019)**
|
| | | | 56.35 | | | | | | 54,000 | | | | | | 1 | | | | | | 17 | | |
Grant (October 2019)**
|
| | | | 56.97 | | | | | | 150,660 | | | | | | 1 | | | | | | 17 | | |
Granted at December 31, 2019
|
| | | | | | | | | | 1,932,156 | | | | | | 1 | | | | | | 17 | | |
可于2019年12月31日起行使的认股权证
|
| | | | | | | | | | – | | | | | | 1 | | | | | | 17 | | |
Number of warrants held
|
| |
January 1,
2018 |
| |
Granted**
|
| |
December 31,
2018 |
| |
Granted**
|
| |
December 31,
2019 |
| |||||||||||||||
Thomas William Wylonis
|
| | | | 293,364 | | | | | | 49,248 | | | | | | 342,612 | | | | | | – | | | | | | 342,612 | | |
Steven Projan
|
| | | | – | | | | | | 23,436 | | | | | | 23,436 | | | | | | – | | | | | | 23,436 | | |
Roberto Prego
|
| | | | 7,416 | | | | | | 12,384 | | | | | | 19,800 | | | | | | – | | | | | | 19,800 | | |
Roberto Prego Novo (former)
|
| | | | 115,092 | | | | | | 4,356 | | | | | | 119,448 | | | | | | – | | | | | | 119,448 | | |
Joann Suzich
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
董事会总数
|
| | | | 415,872 | | | | | | 89,424 | | | | | | 505,296 | | | | | | – | | | | | | 505,296 | | |
Lars Aage Staal Wegner
|
| | | | 840,528 | | | | | | 3,888 | | | | | | 844,416 | | | | | | – | | | | | | 844,416 | | |
Thomas Bogenrieder
|
| | | | 4,356 | | | | | | – | | | | | | 4,356 | | | | | | 45,216 | | | | | | 49,572 | | |
Glenn S. Vraniak
|
| | | | – | | | | | | – | | | | | | – | | | | | | 150,660 | | | | | | 150,660 | | |
高管管理合计
|
| | | | 844,884 | | | | | | 3,888 | | | | | | 848,772 | | | | | | 195,876 | | | | | | 1,044,648 | | |
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
Finance income: | | | | | | | | | | | | | |
Interest income, bank
|
| | | $ | 2 | | | | | $ | 8 | | |
Interest income, other
|
| | | | – | | | | | | 1 | | |
Foreign exchange gains
|
| | | | 74 | | | | | | 56 | | |
Total financial income
|
| | | | 76 | | | | | | 65 | | |
Finance expenses: | | | | | | | | | | | | | |
Interest expenses
|
| | | | (10) | | | | | | (36) | | |
可转换债务工具公允价值变动
|
| | | | (684) | | | | | | (1,183) | | |
利息支出、租赁负债
|
| | | | (4) | | | | | | (3) | | |
汇兑损失
|
| | | | (21) | | | | | | – | | |
财务费用总额
|
| | | | (719) | | | | | | (1,222) | | |
Net financial items
|
| | | $ | (643) | | | | | $ | (1,157) | | |
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
Income taxes
|
| | | $ | (735) | | | | | $ | (825) | | |
本年度所得税总额
|
| | | $ | (735) | | | | | $ | (825) | | |
| | |
Years Ended December 31,
|
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
丹麦法定企业所得税税率
|
| | | | 22% | | | | | | 22% | | |
不可扣除的费用
|
| | | | (10)% | | | | | | (5)% | | |
税收抵免研发支出
|
| | | | 12% | | | | | | 7% | | |
未资本化的递延税项资产变动
|
| | | | (12)% | | | | | | (17)% | | |
Total effective tax rate
|
| | | | 12% | | | | | | 7% | | |
| | |
December 31,
|
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
递延纳税头寸 | | | | | | | | | | | | | |
Warrants
|
| | | $ | 1,463 | | | | | $ | 3,034 | | |
Loss carry forward
|
| | | | 136 | | | | | | 1,270 | | |
Other items
|
| | | | 48 | | | | | | (34) | | |
递延税项资产计价准备
|
| | | | (1,647) | | | | | | (4,270) | | |
未确认递延税金负债总额
|
| | | $ | – | | | | | $ | – | | |
| | |
Years Ended December 31,
|
| |||||||||
(美元以千为单位,不包括每股金额和每股金额)
|
| |
2018
|
| |
2019
|
| ||||||
稀释前后每股亏损 | | | | | | | | | | | | | |
Evaxion Biotech A/S股东应占净亏损
|
| | | $ | (5,535) | | | | | $ | (11,195) | | |
加权平均已发行普通股数量
|
| | | | 12,917,016 | | | | | | 13,892,314 | | |
稀释前后每股亏损
|
| | | $ | (0.43) | | | | | $ | (0.81) | | |
| | |
December 31,
|
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
Warrants
|
| | | | 1,674,324 | | | | | | 2,059,128 | | |
Convertible Debt l
|
| | | | 302,976 | | | | | | – | | |
Convertible Debt 2
|
| | | | 827,856 | | | | | | – | | |
(USD in thousands)
|
| |
Property
|
| |
Other
Equipment |
| |
Total
|
| |||||||||
Cost at January 1, 2018
|
| | | $ | 172 | | | | | $ | 27 | | | | | $ | 199 | | |
本年度新增数量
|
| | | | 7 | | | | | | 7 | | | | | | 14 | | |
汇率调整
|
| | | | (8) | | | | | | (2) | | | | | | (10) | | |
Cost at December 31, 2018
|
| | | | 171 | | | | | | 32 | | | | | | 203 | | |
Depreciation at January 1, 2018
|
| | | | (12) | | | | | | (6) | | | | | | (18) | | |
本年度折旧
|
| | | | (70) | | | | | | (7) | | | | | | (77) | | |
汇率调整
|
| | | | 3 | | | | | | 1 | | | | | | 4 | | |
Depreciation at December 31, 2018
|
| | | | (79) | | | | | | (12) | | | | | | (91) | | |
Carrying amount at December 31, 2018
|
| | | $ | 92 | | | | | $ | 20 | | | | | $ | 112 | | |
2018年12月31日使用权资产账面金额
|
| | | $ | 92 | | | | | $ | – | | | | | $ | 92 | | |
| | | | | | | | | | | | | | | | | | | |
(USD in thousands)
|
| |
Property
|
| |
Other
Equipment |
| |
Total
|
| |||||||||
Cost at December 31, 2018
|
| | | $ | 171 | | | | | $ | 32 | | | | | $ | 203 | | |
本年度新增数量
|
| | | | 12 | | | | | | 61 | | | | | | 73 | | |
汇率调整
|
| | | | (4) | | | | | | – | | | | | | (4) | | |
Cost at December 31, 2019
|
| | | | 179 | | | | | | 93 | | | | | | 272 | | |
Depreciation at December 31, 2018
|
| | | | (79) | | | | | | (13) | | | | | | (92) | | |
本年度折旧
|
| | | | (67) | | | | | | (14) | | | | | | (81) | | |
汇率调整
|
| | | | 2 | | | | | | – | | | | | | 2 | | |
Depreciation at December 31, 2019
|
| | | | (144) | | | | | | (27) | | | | | | (171) | | |
Carrying amount at December 31, 2019
|
| | | $ | 35 | | | | | $ | 66 | | | | | $ | 101 | | |
2019年12月31日使用权资产账面金额
|
| | | $ | 35 | | | | | $ | – | | | | | $ | 35 | | |
| | |
Years Ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
研发
|
| | | $ | 58 | | | | | $ | 64 | | |
一般和行政
|
| | | | 15 | | | | | | 16 | | |
全面损失表中包含的折旧总额
|
| | | $ | 73 | | | | | $ | 80 | | |
12月31日使用权资产累计折旧总额
|
| | | $ | 79 | | | | | $ | 145 | | |
| | |
January 1,
2018 |
| |
December 31,
|
| ||||||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||||||||
VAT receivables
|
| | | $ | 26 | | | | | $ | 55 | | | | | $ | 75 | | |
Prepayments
|
| | | | – | | | | | | 148 | | | | | | 451 | | |
向临床研究机构预付款项
|
| | | | 133 | | | | | | 30 | | | | | | 17 | | |
协作伙伴应收账款
|
| | | | 516 | | | | | | – | | | | | | – | | |
Other receivables
|
| | | | 5 | | | | | | 5 | | | | | | 32 | | |
Total receivables
|
| | | $ | 680 | | | | | $ | 238 | | | | | $ | 575 | | |
| | |
January 1,
2018 |
| |
December 31,
|
| ||||||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||||||||
支付给临床研究机构的款项
|
| | | $ | – | | | | | $ | 197 | | | | | $ | 588 | | |
员工成本负债
|
| | | | 159 | | | | | | 226 | | | | | | 275 | | |
Other liabilities
|
| | | | 19 | | | | | | 214 | | | | | | 177 | | |
Total other payables
|
| | | $ | 178 | | | | | $ | 637 | | | | | $ | 1,040 | | |
| | |
January 1,
2018 |
| |
December 31,
|
| ||||||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||||||||
现金和现金等价物
|
| | | $ | 468 | | | | | $ | 7,433 | | | | | $ | 9,559 | | |
现金和现金等价物合计
|
| | | $ | 468 | | | | | $ | 7,433 | | | | | $ | 9,559 | | |
| | |
December 31,
|
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
Changes in receivables
|
| | | $ | 443 | | | | | $ | (337) | | |
贸易应付款变更
|
| | | | 79 | | | | | | 507 | | |
其他应付款的更改
|
| | | | 459 | | | | | | 403 | | |
净营运资金变动
|
| | | $ | 981 | | | | | $ | 573 | | |
| | |
Years ended
December 31, |
| |||||||||
(USD in thousands)
|
| |
2018
|
| |
2019
|
| ||||||
Income taxes
|
| | | $ | (735) | | | | | $ | (825) | | |
Depreciation
|
| | | | 74 | | | | | | 81 | | |
Interest income
|
| | | | (2) | | | | | | (9) | | |
Interest expense
|
| | | | 15 | | | | | | 39 | | |
基于股份的薪酬费用
|
| | | | 2,069 | | | | | | 2,362 | | |
可转换债务工具公允价值变动
|
| | | | 684 | | | | | | 1,183 | | |
Other adjustments:
其他调整,主要是汇率调整 |
| | | | 18 | | | | | | 114 | | |
非现金项目调整合计
|
| | | $ | 2,123 | | | | | $ | 2,945 | | |
|
(USD in thousands)
|
| |
January 1,
2018 |
| |
Cash flows
|
| |
Accumulated
interest |
| |
Fair value
Adjustment |
| |
Additions
|
| |
Conversion
|
| |
Exchange
rate adjustment |
| |
December 31,
2018 |
| ||||||||||||||||||||||||
Lease liabilities
|
| | | $ | 162 | | | | | $ | (67) | | | | | $ | 5 | | | | | $ | – | | | | | $ | 7 | | | | | $ | – | | | | | $ | (8) | | | | | $ | 99 | | |
可转换债务工具
|
| | | | – | | | | | | 7,998 | | | | | | – | | | | | | 684 | | | | | | – | | | | | | – | | | | | | (113) | | | | | | 8,569 | | |
Total liabilities
from financing activities |
| | | $ | 162 | | | | | $ | 7,931 | | | | | $ | 5 | | | | | $ | 684 | | | | | $ | 7 | | | | | $ | – | | | | | $ | (121) | | | | | $ | 8,668 | | |
|
(USD in thousands)
|
| |
December 31,
2018 |
| |
Cash flows
|
| |
Accumulated
interest |
| |
Fair value
adjustment |
| |
Additions
|
| |
Conversion
|
| |
Exchange
rate adjustment |
| |
December 31,
2019 |
| ||||||||||||||||||||||||
Lease liabilities
|
| | | $ | 99 | | | | | $ | (75) | | | | | $ | 2 | | | | | $ | – | | | | | $ | 12 | | | | | $ | – | | | | | $ | (2) | | | | | $ | 36 | | |
可转换债务工具
|
| | | | 8,569 | | | | | | 152 | | | | | | – | | | | | | 1,183 | | | | | | – | | | | | | (9,695) | | | | | | (209) | | | | | | – | | |
Total liabilities
from financing activities |
| | | $ | 8,668 | | | | | $ | 77 | | | | | $ | 2 | | | | | $ | 1,183 | | | | | $ | 12 | | | | | $ | (9,695) | | | | | $ | (211) | | | | | $ | 36 | | |
(USD in thousands)
|
| |
Right-of-Use Asset
|
| |
Lease liabilities
|
| ||||||
At January 1, 2018
|
| | | $ | 160 | | | | | $ | 162 | | |
Additions
|
| | | | 7 | | | | | | 7 | | |
Depreciation
|
| | | | (70) | | | | | | – | | |
Interest Expense
|
| | | | – | | | | | | 5 | | |
Payments
|
| | | | – | | | | | | (67) | | |
Translation
|
| | | | (5) | | | | | | (8) | | |
At December 31, 2018
|
| | | $ | 92 | | | | | $ | 99 | | |
|
(USD in thousands)
|
| |
Right-of-Use Asset
|
| |
Lease liabilities
|
| ||||||
At December 31, 2018
|
| | | | 92 | | | | | | 99 | | |
Additions
|
| | | | 12 | | | | | | 12 | | |
Depreciation
|
| | | | (67) | | | | | | – | | |
Interest Expense
|
| | | | – | | | | | | 2 | | |
Payments
|
| | | | – | | | | | | (75) | | |
Translation
|
| | | | (2) | | | | | | (2) | | |
At December 31, 2019
|
| | | | 35 | | | | | | 36 | | |
| | |
Number of
Ordinary Shares |
| |
Share Capital
(DKK in thousands) |
| ||||||
Share capital, January 1, 2018
|
| | | | 12,917,016 | | | | | | 12,917 | | |
Share capital, December 31, 2018
|
| | | | 12,917,016 | | | | | | 12,917 | | |
2019年7月17日增资(发行股票换现金)
|
| | | | 997,668 | | | | | | 998 | | |
2019年7月17日增资(可转债转换1)
|
| | | | 302,976 | | | | | | 303 | | |
2019年7月17日增资(可转债转换2)
|
| | | | 848,232 | | | | | | 848 | | |
2019年12月19日增资(发行股票换现金)
|
| | | | 118,260 | | | | | | 118 | | |
Share capital, December 31, 2019
|
| | | | 15,184,152 | | | | | | 15,184 | | |
| | |
January 1,
2018 |
| |
December 31,
|
| ||||||||||||
(美元以千为单位,不包括份额)
|
| |
2018
|
| |
2019
|
| ||||||||||||
已分配、已调用并已全额支付 | | | | | | | | | | | | | | | | | | | |
15,184,152 (2018: 12,917,016) ordinary shares of DKK 1 each (2018: ordinary shares of DKK 1 each)
|
| | | $ | 2,113 | | | | | $ | 2,113 | | | | | $ | 2,481 | | |
| | | | $ | 2,113 | | | | | $ | 2,113 | | | | | $ | 2,481 | | |
拥有的普通股数量
|
| |
2018
|
| |
2019
|
| ||||||
Niels Iversen Møller
|
| | | | 4,292,352 | | | | | | 4,292,604 | | |
Andreas Holm Mattsson
|
| | | | 4,163,832 | | | | | | 4,163,832 | | |
Lars Aage Staal Wegner
|
| | | | 181,872 | | | | | | 182,124 | | |
高管管理合计
|
| | | | 8,368,056 | | | | | | 8,638,560 | | |
|
拥有的普通股数量
|
| |
2018
|
| |
2019
|
| ||||||
Roberto Prego
|
| | | | 307,548 | | | | | | 310,248 | | |
Thomas William Wylonis
|
| | | | 471,096 | | | | | | 481,860 | | |
Steven Projan
|
| | | | – | | | | | | 11,736 | | |
董事会总数
|
| | | | 778,644 | | | | | | 803,844 | | |
(USD in thousands)
|
| |
Convertible loans
|
| |||
Carrying amount at January 1, 2018
|
| | | $ | – | | |
Amount received in 2018
|
| | | | 7,998 | | |
计入财务费用的公允价值调整
|
| | | | 684 | | |
Currency adjustment
|
| | | | (113) | | |
Carrying amount at December 31, 2018
|
| | | | 8,569 | | |
Amount received in 2019
|
| | | | 152 | | |
计入财务费用的公允价值调整
|
| | | | 1,183 | | |
Currency adjustment
|
| | | | (209) | | |
Converted to equity during 2019
|
| | | | (9,695) | | |
Carrying amount at December 31, 2019
|
| | | $ | – | | |
| | |
Assumption applied
|
|
DKK/USD exchange rate
|
| |
0.154
|
|
Discount rate
|
| |
Convertible Debt 1 – 39%
Convertible Debt 2 – 25% |
|
符合条件的融资事件发生的概率
|
| |
95%
|
|
Evaxion share price
|
| |
$5.75
|
|
(USD in thousands)
|
| |
Impact on
Convertible Debt 1 |
| |
Impact on
Convertible Debt 2 |
| ||||||
Exchange rate increased by 5%
|
| | | $ | (48) | | | | | $ | (272) | | |
Exchange rate decreased by 5%
|
| | | $ | 48 | | | | | $ | 272 | | |
Discount rate decreased by 3%
|
| | | $ | (24) | | | | | $ | (85) | | |
融资事件概率降低25%
|
| | | $ | (100) | | | | | $ | (40) | | |
Share price increased by 10%
|
| | | $ | (10) | | | | | $ | (39) | | |
Share price decreased by 10%
|
| | | $ | 10 | | | | | $ | 39 | | |
| | |
December 31,
|
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
公司与其他关联方的交易: | | | | | | | | | | | | | |
(USD in thousands) | | | | | | | | | | | | | |
关联方交易(费用): | | | | | | | | | | | | | |
发行给执行管理层和董事会成员的可转换债务工具的应计利息
|
| | | $ | (4) | | | | | $ | (4) | | |
年末关联方余额(资产)
|
| | | $ | – | | | | | $ | – | | |
年末关联方余额(负债): | | | | | | | | | | | | | |
向执行管理层和董事会成员发行的可转换债务工具(名义价值外加7.5%的应计利息)
|
| | | $ | 117 | | | | | $ | – | | |
| | |
December 31, 2019
|
| |||||||||||||||||||||||||||
(USD in thousands)
|
| |
Contractual
cash flows |
| |
Year
|
| |
1 – 2
years |
| |
2 – 5
years |
| |
>5 years
|
| |||||||||||||||
Purchase obligations
|
| | | $ | 710 | | | | | $ | 587 | | | | | $ | 103 | | | | | $ | 20 | | | | | $ | – | | |
Total
|
| | | $ | 710 | | | | | $ | 587 | | | | | $ | 103 | | | | | $ | 20 | | | | | $ | – | | |
| | | | | |
截至9月30日的9个月
|
| | |||||||||||
| | |
Note
|
| |
2019
|
| |
2020
|
| | ||||||||
| | | | | |
(单位为千美元,每股除外)
|
| | | | |||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | ||
研发
|
| | | | | | $ | 5,270 | | | | | $ | 8,048 | | | | ||
一般和行政
|
| | | | | | | 1,870 | | | | | | 3,875 | | | | ||
总运营费用
|
| | | | | | | 7,140 | | | | | | 11,923 | | | | ||
Operating loss
|
| | | | | | | (7,140) | | | | | | (11,923) | | | | ||
Finance income
|
| | | | | | | 84 | | | | | | 123 | | | | ||
Finance expenses
|
| | | | | | | (1,186) | | | | | | (9) | | | | ||
Net loss before tax
|
| | | | | | | (8,242) | | | | | | (11,809) | | | | ||
Income taxes
|
| | | | | | | 566 | | | | | | 1,055 | | | | ||
Net loss for the period
|
| | | | | | $ | (7,676) | | | | | $ | (10,754) | | | | ||
Evaxion Biotech A/S股东应占净亏损
|
| | | | | | $ | (7,676) | | | | | $ | (10,754) | | | | ||
可能重新分类为
的其他全面收入
后续期间损益(税后净额): |
| | | | | | | | | | | | | | | | | ||
对外业务翻译汇兑差异
|
| | | | | | | — | | | | | | (6) | | | | ||
后续期间不重新分类为损益的其他全面收入(税后净额):
|
| | | | | | | | | | | | | | | | | ||
货币折算成提示货币的汇兑差额
|
| | | | | | | (278) | | | | | | 20 | | | | | |
当期其他综合损益,税后净额
|
| | | | | | $ | (278) | | | | | $ | 14 | | | | ||
全面亏损
|
| | | | | | $ | (7,954) | | | | | $ | (10,740) | | | | ||
Evaxion Biotech A/S股东应占全面亏损总额
|
| | | | | | $ | (7,954) | | | | | $ | (10,740) | | | | ||
Loss per share – basic and diluted
|
| | | | | | $ | (0.57) | | | | | $ | (0.71) | | | |
| | |
Note
|
| |
December 31,
2019 |
| |
September 30,
2020 |
| ||||||
| | | | | | | | | | | |
(unaudited)
|
| |||
| | | | | |
(USD in thousands)
|
| |||||||||
ASSETS | | | | | | | | | | | | | | | | |
Non-current assets | | | | | | | | | | | | | | | | |
Intangible assets
|
| |
2
|
| | | $ | — | | | | | $ | 37 | | |
财产、厂房和设备
|
| | | | | | | 101 | | | | | | 166 | | |
Tax receivables
|
| | | | | | | — | | | | | | 612 | | |
Leasehold deposits
|
| | | | | | | 25 | | | | | | 47 | | |
非流动资产合计
|
| | | | | | | 126 | | | | | | 862 | | |
Current assets | | | | | | | | | | | | | | | | |
Receivables
|
| | | | | | | 575 | | | | | | 1,431 | | |
延期发售成本
|
| |
2
|
| | | | — | | | | | | 631 | | |
Tax receivables
|
| | | | | | | 824 | | | | | | 475 | | |
现金和现金等价物
|
| | | | | | | 9,559 | | | | | | 7,876 | | |
Total current assets
|
| | | | | | | 10,958 | | | | | | 10,413 | | |
TOTAL ASSETS
|
| | | | | | $ | 11,084 | | | | | $ | 11,275 | | |
权益和负债 | | | | | | | | | | | | | | | | |
Share capital
|
| |
5
|
| | | $ | 2,481 | | | | | $ | 2,603 | | |
Other reserves
|
| | | | | | | 22,693 | | | | | | 29,067 | | |
Accumulated deficit
|
| | | | | | | (15,812) | | | | | | (23,767) | | |
Total equity
|
| | | | | | | 9,362 | | | | | | 7,903 | | |
流动负债 | | | | | | | | | | | | | | | | |
Lease liabilities
|
| | | | | | | 36 | | | | | | 38 | | |
Trade payables
|
| | | | | | | 646 | | | | | | 1,502 | | |
Other payables
|
| | | | | | | 1,040 | | | | | | 1,832 | | |
流动负债总额
|
| | | | | | | 1,722 | | | | | | 3,372 | | |
Total liabilities
|
| | | | | | | 1,722 | | | | | | 3,372 | | |
权益和负债合计
|
| | | | | | $ | 11,084 | | | | | $ | 11,275 | | |
| | | | | | | | | | | |
Other reserves
|
| | | | | | | | | | | | | |||||||||
| | |
Note
|
| |
Share
capital |
| |
Share
premium |
| |
Foreign
currency translation reserve |
| |
Accumulated
deficit |
| |
Total
equity |
| |||||||||||||||
Equity at December 31, 2018
|
| | | | | | $ | 2,113 | | | | | $ | 4,106 | | | | | $ | (171) | | | | | $ | (6,979) | | | | | $ | (931) | | |
Net loss for the period
|
| | | | | | | | | | | | | | | | | | | | | | | | | (7,676) | | | | | | (7,676) | | |
其他综合收益
|
| | | | | | | | | | | | | | | | | | | (278) | | | | | | | | | | | | (278) | | |
基于股份的薪酬费用
|
| | | | | | | | | | | | | | | | | | | | | | | | | 1,725 | | | | | | 1,725 | | |
发行股票换取现金
|
| | | | | | | 163 | | | | | | 8,273 | | | | | | | | | | | | | | | | | | 8,436 | | |
Transaction costs
|
| | | | | | | | | | | | | (13) | | | | | | | | | | | | | | | | | | (13) | | |
可转换债务工具结算
|
| | | | | | | 187 | | | | | | 9,508 | | | | | | | | | | | | | | | | | | 9,695 | | |
Equity at September 30, 2019
|
| | | | | | $ | 2,463 | | | | | $ | 21,874 | | | | | $ | (449) | | | | | $ | (12,930) | | | | | $ | 10,958 | | |
|
| | | | | | | | | | | |
Other reserves
|
| | | | | | | | | | | | | |||||||||
| | |
Note
|
| |
Share
capital |
| |
Share
premium |
| |
Foreign
currency translation reserve |
| |
Accumulated
deficit |
| |
Total
equity |
| |||||||||||||||
Equity at December 31, 2019
|
| | | | | | $ | 2,481 | | | | | $ | 22,862 | | | | | $ | (169) | | | | | $ | (15,812) | | | | | $ | 9,362 | | |
Net loss for the period
|
| | | | | | | | | | | | | | | | | | | | | | | | | (10,754) | | | | | | (10,754) | | |
其他综合收益
|
| | | | | | | | | | | | | | | | | | | 14 | | | | | | | | | | | | 14 | | |
基于股份的薪酬费用
|
| | | | | | | | | | | | | | | | | | | | | | | | | 2,799 | | | | | | 2,799 | | |
发行股票换取现金
|
| |
5
|
| | | | 122 | | | | | | 6,504 | | | | | | | | | | | | | | | | | | 6,626 | | |
Transaction costs
|
| |
5
|
| | | | | | | | | | (144) | | | | | | | | | | | | | | | | | | (144) | | |
Equity at September 30, 2020
|
| | | | | | $ | 2,603 | | | | | $ | 29,222 | | | | | $ | (155) | | | | | $ | (23,767) | | | | | $ | 7,903 | | |
| | | | | |
截至9月30日的9个月
|
| |||||||||
| | |
Note
|
| |
2019
|
| |
2020
|
| ||||||
| | | | | |
(USD in thousands)
|
| |||||||||
经营活动: | | | | | | | | | | | | | | | | |
Net loss for the period
|
| | | | | | $ | (7,676) | | | | | $ | (10,754) | | |
非现金项目调整
|
| |
5
|
| | | | 2,313 | | | | | | 1,814 | | |
非流动金融资产 - 租赁存款变动
|
| | | | | | | (7) | | | | | | (20) | | |
Interest received
|
| | | | | | | 1 | | | | | | — | | |
Interest paid
|
| | | | | | | (2) | | | | | | (1) | | |
Income taxes received
|
| | | | | | | — | | | | | | 812 | | |
营运资金变动前的经营活动现金流
|
| | | | | | | (5,371) | | | | | | (8,149) | | |
营运资金变动产生的现金流:
|
| | | | | | | | | | | | | | | |
净营运资金变动
|
| | | | | | | 559 | | | | | | 104 | | |
经营活动中使用的净现金
|
| | | | | | | (4,812) | | | | | | (8,045) | | |
投资活动: | | | | | | | | | | | | | | | | |
购置房产、厂房和设备
|
| | | | | | | (14) | | | | | | (77) | | |
购买无形资产
|
| |
2
|
| | | | — | | | | | | (35) | | |
投资活动中使用的净现金
|
| | | | | | | (14) | | | | | | (112) | | |
融资活动: | | | | | | | | | | | | | | | | |
股票发行收益
|
| |
6
|
| | | | 8,436 | | | | | | 6,626 | | |
发行股票的预付收益
|
| |
6
|
| | | | 744 | | | | | | — | | |
与发行股票相关的交易成本
|
| |
6
|
| | | | (13) | | | | | | (128) | | |
发行可转换债务工具所得收益
|
| | | | | | | 152 | | | | | | — | | |
Leasing installments
|
| | | | | | | (55) | | | | | | (54) | | |
融资活动提供的现金净额
|
| | | | | | | 9,264 | | | | | | 6,444 | | |
现金及现金等价物净增(减)
|
| | | | | | | 4,438 | | | | | | (1,713) | | |
年初现金和现金等价物
|
| | | | | | | 7,433 | | | | | | 9,559 | | |
现金和现金等价物的汇率调整
|
| | | | | | | (400) | | | | | | 30 | | |
现金和现金等价物,期末
|
| | | | | | $ | 11,471 | | | | | $ | 7,876 | | |
| | |
September 30, 2020
|
| |||||||||||||||||||||||||||||||||
(USD in thousands)
|
| |
Carrying
amount |
| |
Contractual
cash flows |
| |
|
| |
1 – 5years
|
| |
>5 years
|
| |
Total
|
| ||||||||||||||||||
Lease liabilities
|
| | | $ | 38 | | | | | $ | 38 | | | | | $ | 38 | | | | | $ | — | | | | | $ | — | | | | | $ | 38 | | |
Trade payables
|
| | | | 1,502 | | | | | | 1,502 | | | | | | 1,502 | | | | | | — | | | | | | — | | | | | | 1,502 | | |
Other payables
|
| | | | 1,832 | | | | | | 1,832 | | | | | | 1,832 | | | | | | — | | | | | | — | | | | | | 1,832 | | |
Total
|
| | | $ | 3,372 | | | | | $ | 3,372 | | | | | $ | 3,372 | | | | | $ | — | | | | | $ | — | | | | | $ | 3,372 | | |
| | | | | | | | | | | |
% equity interest
|
| |||||||||
Name
|
| |
Principal activities
|
| |
Country of
incorporation |
| |
December 31,
2019 |
| |
September 30,
2020 |
| |||||||||
Evaxion Biotech A/S
|
| |
Pharmaceutical R&D
|
| | | | 丹麦 | | | | | | 100 | | | | | | 100 | | |
Evaxion Biotech Australia Pty Ltd
|
| |
Pharmaceutical R&D
|
| | | | 澳大利亚 | | | | |
|
—
|
| | | | | 100 | | |
Participants
|
| |
Estimated
Number of warrants |
| |
Fair value(1)
|
| |
Vesting Term
|
| |
Exercise Price
(DKK) |
| |||||||||
Employees
|
| | | | 73,656 | | | | | $ | 70万 | | | |
3 years
|
| | | | 1 | | |
Employees
|
| | | | 20,628(2) | | | | | $ | 20万 | | | |
Immediate
|
| | | | 1 | | |
科学顾问委员会
|
| | | | 20,304 | | | | | $ | 20万 | | | |
Immediate
|
| | | | 1 | | |
Board of Directors
|
| | | | 27,828 | | | | | $ | 20万 | | | |
Immediate
|
| | | | 1 | | |
| | |
截至9月30日的9个月
|
| | |||||||||||
(USD in thousands)
|
| |
2019
|
| |
2020
|
| | ||||||||
研发费用
|
| | | $ | 749 | | | | | $ | 1,321 | | | | ||
一般和行政费用
|
| | | | 976 | | | | | | 1,462 | | | | ||
Total
|
| | | $ | 1,725 | | | | | $ | 2,783* | | | | | |
| | |
截至9月30日的9个月
|
| |||||||||
(USD in thousands)
|
| |
2019
|
| |
2020
|
| ||||||
Income taxes
|
| | | $ | (566) | | | | | $ | (1,055) | | |
Depreciation
|
| | | | 51 | | | | | | 76 | | |
Interest income
|
| | | | (1) | | | | | | (1) | | |
Interest expense
|
| | | | 2 | | | | | | 1 | | |
基于股份的薪酬费用
|
| | | | 1,725 | | | | | | 2,783 | | |
可转换债务工具公允价值变动
|
| | | | 1,183 | | | | | | — | | |
Other adjustments: | | | | | | | | | | | | | |
其他调整,主要是汇率调整
|
| | | | (81) | | | | | | 10 | | |
非现金项目调整合计
|
| | | $ | 2,313 | | | | | $ | 1,814 | | |
| | |
Number of
Ordinary Shares |
| |
Share Capital
(DKK in thousands) |
| ||||||
Share capital, December 31, 2018
|
| | | | 12,917,016 | | | | | | 12,917 | | |
2019年7月17日增资(发行股票换现金)
|
| | | | 997,668 | | | | | | 998 | | |
2019年7月17日增资(转换可转换债券)
Debt 1) |
| | | | 302,976 | | | | | | 303 | | |
2019年7月17日增资(转换可转换债券)
Debt 2) |
| | | | 848,232 | | | | | | 848 | | |
Share capital, September 30, 2019
|
| | | | 15,065,892 | | | | | | 15,066 | | |
Share capital, December 31, 2019(1)
|
| | | | 15,184,152 | | | | | | 15,184 | | |
2020年9月17日增资(发行股票)
cash) |
| | | | 745,380 | | | | | | 745 | | |
Share capital, September 30, 2020
|
| | | | 15,929,532 | | | | | | 15,930 | | |
(美元以千为单位,不包括份额)
|
| |
December 31,
2019 |
| |
September 30,
2020 |
| ||||||
已分配、已调用并已全额支付 | | | | | | | | | | | | | |
15,929,532 (2019: 15,184,152) Ordinary shares of DKK 1 each
|
| | | $ | 2,481 | | | | | $ | 2,603 | | |
| | | | $ | 2,481 | | | | | $ | 2,603 | | |